Safety Study of CNT-01 in Patients With Idiopathic TGCV

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2016

Conditions
Idiopathic Triglyceride Deposit Cardiomyovasculopathy
Interventions
DRUG

CNT-01 500 mg capsule

After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.

Trial Locations (1)

565-0871

Cardiovascular Medicine, Osaka University Hospital, Suita

All Listed Sponsors
lead

Osaka University

OTHER

NCT02502578 - Safety Study of CNT-01 in Patients With Idiopathic TGCV | Biotech Hunter | Biotech Hunter